Vodobatinib was synthesized by researchers at SPARC to help patients with CML who no longer respond to their previous medications or can’t tolerate them due to side effects.
We are actively enrolling patients into this international Phase II trial. Please click here to get more information about this trial for you and your doctor to see if this clinical trial may be appropriate for you.